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ABSTRACT 
Neuropeptides are cell-to-cell signaling molecules that act as neurotransmitters, 
neuromodulators and hormones that impact a large variety of neuronal processes. The term 
neuropeptide refers to bioactive peptides made in neuron, stored in vesicles, and released into the 
extracellular space. While many peptides can be detected in a tissue homogenate, these will 
include processing intermediates and even protein degradation products. It is of great interest in 
the field of peptidomics to focus on functional characterization of proteins products such as cell-
to-cell signaling peptides that are released from specific neuronal tissues, whether a brain region 
or specific cell.  A variety of analytical techniques have emerged over the years to analyze 
neuropeptide release, and these methods have enabled scientists to characterize thousands of 
brain peptides. The focus of this research was on using various sampling approaches coupled to 
matrix-assisted laser desorption/ionization-mass spectrometry (MALDI MS) to analyze 
neuropeptide release from rodent brains. Chapter 2 is a general overview of the current state of 
analytical methods used to characterize neuropeptide release from cells to animals. Chapter 3 
highlights two methods demonstrating neuropeptide release in a mouse model of fragile X 
syndrome.  Sampling techniques using synaptoneurosomes and ex vivo brain slices were used to 
show a neuropeptide release deficit in Fmr1 KO mice. Chapter 4 highlights an approach utilizing 
in vivo microdialysis coupled to offline MALDI MS. This method was used to characterize 
extracellular peptide release from the hippocampus of rats in response to saline or morphine 
injection coupled with a spontaneous alternation task. In particular, fibrinopeptide A, a peptide 
derived from the fibrinogen α-chain, was significantly upregulated in rats exposed to morphine 
and spontaneous alternation testing. The functional consequence of fibronopeptide A release is 
still under investigation. The advancement of such analytical approaches to characterize 
neuropeptide release from a variety of samples ranging from cells to animals enables new 
discovery efforts for understanding the physiological and behavioral role of unknown peptides. 
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CHAPTER 1 
 
OVERVIEW 
 
Advances in mass spectrometry (MS) have allowed thousands of peptides to be 
characterized from brain regions. The focus of this dissertation is on using analytical methods 
coupled to MS to analyze neuropeptide release in rodents.  Compared to peptide expression 
studies such as radioimmunoassay and immunohistochemistry, MS-based studies of peptide 
release allow for more specific temporal investigation and characterization of peptides more 
likely to be biologically active. Examining peptides that have been released from neurons 
provides valuable information about signaling, and in turn, can help pinpoint the physiological 
actions/roles of specific neuropeptides. In addition, by studying release, a distinction can be 
made between peptides that are released and play a role in cell-to-cell signaling versus other 
functions. In other words, information on peptide release provides a functional context, even for 
newly discovered brain peptides.  
A variety of analytical techniques have been developed to analyze neuropeptide release, 
some of which will be further discussed in this dissertation. Chapter 2 is an overview of the 
history and current state of these methods. Chapters 3 & 4 focus specifically on using MALDI 
MS as an analytical tool to characterize neuropeptide release in mice and rats. In particular, 
Chapter 3 focused on two methods used to analyze neuropeptide release in a mouse model of 
FXS, the most common cause of mental retardation. The motivation for this research was 
prompted by the discovery that there might be presynaptic effects caused by the loss of FMRP.  
Utilizing in vitro synaptoneurosomes and ex vivo brain slices and combining these methods with 
analytical MS, it was found that Fmr1 KO mice exhibit neuropeptide release deficit. Rab3A, a 
GTPAse involved in the vesicle release machinery, was also found to be reduced in Fmr1 KO 
mice. Interestingly, DCV quantity is normal in Fmr1 KO mice. Using electrochemistry, the 
release deficit was shown to be specific to peptides, as there is no significant difference in the 
release of DA, 5-HT, and NE from the striatum of WT and Fmr1 KO mice. Together, these 
findings offer intriguing future directions into elucidating the molecular mechanism of defective 
neuropeptide release in FXS. Chapter 4 focuses on an approach utilizing in vivo microdialysis 
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coupled to offline MALDI MS. This method was used to examine the effects of morphine on 
peptide release in the hippocampus. Two peptides derived from the fibrinogen α-chain were 
found to be consistently increased in the hippocampal microdialysate. One of the peptides was 
fibrinopeptide A (m/z 1738.80); the other was a fibrinopeptide A-derived peptide (m/z 1667.76) 
that results from the cleavage between amino acids A and D in the N-terminus. In particular, 
fibrinopeptide A was significantly upregulated in rats that had been given a morphine injection 
and placed on a four-arm radial maze to perform a spontaneous alternation task compared with 
other experimental rat groups. Recently, there has been work to support the expression of 
fibrinogen in the brain, but it a rather novel finding. It is speculated the interplay between 
morphine and fibrinogen is rather complex. The in vivo microdialysis work provides a useful 
finding into uncovering this relationship. Morphine has analgesic effects and interestingly, 
fibrinogen degradation products have been found to potentiate the actions of morphine. It is also 
possible that morphine is directly involved in increasing peptide release, as it has been show to 
increase neurotransmitter release. Furthermore, fibrinogen is a glycoprotein involved in the 
blood clotting pathway and it is also possible that other proteins in the pathway are affected. 
Future work utilizing other molecular methods will help elucidate the relationship between 
morphine and fibrinogen.  
In conclusion, the methods utilized in this dissertation work provide useful information to 
the field of FXS, morphine, and peptidomics research. It is with high hopes that researchers will 
be able to utilize this work in the further advancements of analytical tools to characterize 
peptides and clinical therapeutics for FXS and morphine abuse.   
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CHAPTER 2 
 
CHARACTERIZING NEUROPEPTIDE RELEASE:  
FROM ISOLATED CELLS TO INTACT ANIMALS 
 
2.1 Notes and Acknowledgements 
This chapter is to be published in its entirety as a monograph chapter entitled 
“Characterizing Neuropeptide Release: From Isolated Cells to Intact Animals” in the book 
Advances in Real-Time Molecular Neuroscience by World Scientific Publishing Co. Maki AE, 
Sweedler JV (2014) Characterizing Neuropeptide Release: From Isolated Cells to Intact 
Animals. In: Wilson GS and Michael AC (Eds) Advances in Real-Time Molecular Neuroscience. 
Hackensack, NJ: World Scientific Publishing Company. In press. The chapter has been adapted 
and reprinted with permission from the publisher. My role was in writing of the publication as 
the primary coauthor. I would like to acknowledge Professor Jonathan Sweedler for giving me 
the unique opportunity to write this chapter.  
Preparation of this manuscript was supported in part by the National Institute on Drug 
Abuse, Award No. P30 DA018310, and the National Institute of Mental Health Award No. R21 
MH100704. 
 
2.2 Introduction 
Neuropeptides, cell-to-cell signaling molecules that act as neurotransmitters, 
neuromodulators or hormones, impact a large variety of neuronal processes. The term 
neuropeptides defines peptides that are made in neurons and synthesized from larger precursor 
proteins called prohormones (Strand, 1999). These prohormones are stored in vesicles along with 
processing enzymes that cleave the prohormone into multiple smaller peptides, some of which 
eventually become bioactive (Hökfelt et al., 2000; Seidah and Chretien, 1997; Steiner, 1998). 
Peptides also undergo posttranslational modifications such as C-terminal amidation, acetylation, 
glycosylation, phosphorylation, and sulfation (Hökfelt et al., 2000). The process of neuropeptide 
synthesis includes: (1) expression of a preprohormone gene, which synthesizes the 
preprohormone in the endoplasmic reticulum, (2) signal peptide cleavage (often occurring before 
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the end of expression) at which point the intact preprohormone is called a prohormone, (3) 
processing of the prohormone in the Golgi apparatus, and (4) packaging into dense-core vesicles 
where further processing occurs. This process results in the production of a single biologically 
active peptide or a variety of peptides that are cell- or context-specific.   
After cleavage, the type of peptides generated varies greatly for different prohormones 
(Hökfelt et al., 2000). Some prohormones yield a series of related peptides, such as 
proenkephalin yielding the enkephalin peptides with similar biological effects (Reiner, 1987). In 
contrast, the proopiomelanocortin prohormone gives rise to a number of biologically active 
peptide products, which include adrenocorticotropin, α-melanocyte-stimulating hormone (MSH), 
β-lipotropin, β-MSH, β-endorphin, and γ-MSH, in addition to some peptides that appear to be 
biologically inert (de Wied, 1999; Hökfelt et al., 2000; Strand, 1999). These are examples of 
“classical” neuropeptides that can be identified from a known prohormone. The synthesis of 
classical neuropeptides takes place within the secretory pathway. Unlike classical transmitters, 
they are released upon simulation from a range of locations including the soma, terminal or even 
neuronal processes (Bruns and Jahn, 1995; Fricker and Sweedler, 2010). Once released, 
biologically active peptides participate in complex signaling pathways involving a variety of 
cellular receptors, mostly G-protein coupled receptors. Another category of peptides, “non-
classical” neuropeptides, are processed from non-secretory proteins and not prohormones 
(Fricker, 2010; Gelman and Fricker, 2010). They are more challenging to identify because they 
are not derived from known precursor molecules. These peptides may be constitutively released 
and include fragments from nuclear, lysosomal, mitochondrial, and membrane proteins (Fricker, 
2010). Due to the complexity of neuropeptide synthesis and processing, in order to characterize 
neuropeptides from tissues, sensitive and versatile methods of analysis are needed.  
Although many peptides can be detected in a tissue homogenate, these samples will 
include processing intermediates and even degradation products from peptides after release. 
Given that many peptides interact with their cognate receptor based on only a partial sequence, 
processing intermediates can have substantial bioactivity, even if they are never released. Thus, 
while a peptidomics experiment can generate long lists of peptides from a brain region (Clynen 
et al., 2010; Lee et al., 2010; Svensson et al., 2007), and some may have activity against the 
appropriate receptor, they still may not be biologically active peptides because they are not 
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released.  Techniques that are capable of characterizing peptides released from specific neuronal 
tissues, whether a brain region or specific cell, are of great interest to the field of peptidomics.  
A variety of methodologies have emerged for analyzing neuropeptide release: sampling 
approaches such as microdialysis, separation approaches such as capillary electrophoresis (CE) 
and liquid chromatography (LC), and detection approaches such as laser induced fluorescence 
(LIF) and mass spectrometry (MS), including electrospray ionization (ESI) and matrix-assisted 
laser desorption/ionization (MALDI).  In this chapter we discuss the evolution of these analytical 
approaches and highlight studies that have used these to characterize neuropeptide release from 
samples ranging from cultured individual cells to intact animals. 
 
2.3 History of Characterizing Neuropeptide Release 
Since their discovery and characterization starting in the late 1960s, neuropeptides have 
been analyzed using a variety of techniques. Radioimmunoassay and immunohistochemistry 
(Yalow and Berson, 1960) are among some of the earliest methods of profiling neuropeptides. In 
particular, immunohistochemistry allows for the localization of a peptide or set of peptides 
through their reactivity to specific antibodies, which can be visualized by fluorescence 
microscopy (Falck et al., 1962). This is a powerful technique for determining the anatomical 
localization and co-localization of peptides. One of the first examples of peptide expression in 
the brain was the discovery of dynorphin peptide in granule cells and their mossy fibers in the 
hippocampus (McGinty et al., 1983; Watson et al., 1982). Another early example reported 
endogenous expression of corticotropin-releasing hormone in olivocerebellar fibers (Palkovits et 
al., 1987; Sakanaka et al., 1987). Although immunohistochemistry is a sensitive method for 
detecting peptide expression, it has drawbacks; it requires analyte preselection and is limited in 
its utility for determining dynamic changes. 
Over the past two decades, chemically information-rich technologies— CE-ESI MS, LC-
ESI MS, direct (with no pre-separation) MALDI MS—have enabled a plethora of novel peptide 
discovery efforts by allowing scientists to characterize literally hundreds of new neuropeptides in 
a range of models (Hummon et al., 2006; Li et al., 2000; Li and Sweedler, 2008). In CE, an 
electric field in a capillary tube is used to separate peptides based on size (Hogan and Yeung, 
1992; Kennedy et al., 1989). Work from the labs of Jorgenson, Ewing, and Yeung pioneered the 
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use of CE-based methods to analyze single cells (Hogan and Yeung, 1992; Kennedy et al., 1989; 
Wallingford and Ewing, 1988). CE is well-suited for single cell analysis due to its optimization 
for smaller sample volumes (Lapainis and Sweedler, 2008; Rubakhin et al., 2011; Rubakhin et 
al., 2013), and when hyphenated to MS, CE has been used for characterizing the metabolome of 
a range of cell types (Lapainis et al., 2009; Nemes et al., 2012). LC is another commonly used 
separation approach for peptide characterization when coupled to ESI MS (Clynen et al., 2010; 
Lee et al., 2010; Svensson et al., 2007). ESI is a soft ionization technique that is well-suited for 
investigating neuropeptides and other larger, easily fragmented peptides (Shibdas and 
Shyamalava, 2012). It allows for the separation of peptides that are structurally quite similar, 
such as one asymmetrical carbon (Smith and Hanley, 1997). It is a high-resolution separation 
method that can rapidly detect neuropeptide expression and release (Strand, 1999). While 
analytical scale LC requires large sample volumes, many neurochemical studies use smaller 
scale LC systems as these are compatible with the smaller volumes available with most 
neurochemical studies (Haskins et al., 2001).  
MALDI MS, a technique first reported in the late 1980s (Karas and Hillenkamp, 1988; 
Tanaka et al., 1988), is one of the more successful methods for studying peptides. Samples are 
co-crystallized with an organic matrix that is then excited by a pulsed laser, leading to desorption 
and ionization of the peptides, and then the ionized peptides are analyzed using the mass 
analyzer, typically time-of-flight (Guerrera and Kleiner, 2005). Using direct MALDI with a 
variety of sampling approaches (Neupert et al., 2012; Rubakhin and Sweedler, 2007; Rubakhin 
and Sweedler, 2008; Rubakhin et al., 2007), a number of peptides have been characterized in a 
range of models such as the common neuronal model Aplysia californica (Jing et al., 2007; Jing 
et al., 2010; Li et al., 2001; Romanova et al., 2012; Sweedler et al., 2002). Lastly, direct MALDI 
MS has evolved as an imaging approach that is capable of providing spatial information on 
peptides from tissues such as brain slices (Chen et al., 2010; Lanni et al., 2012; Monroe et al., 
2008; Sturm et al., 2013).  
Separation and direct MS-based characterization approaches have greatly evolved to 
being quite versatile and sensitive. As highlighted below, they have enabled a wide variety of 
discovery efforts for in vitro, ex vivo, and in vivo samples. 
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2.4 Current Methods of Analyzing Neuropeptide Release 
2.4.1 Cellular Methods 
Measuring neuropeptide release is more difficult than measuring the contents of a cell or 
brain region; releasate contains less material and there are sampling constraints during collection 
(Li and Sweedler, 2008). Progress in peptidomics research has led to the development of a 
variety of analytical methods integrated with CE, LC, and MALDI MS for examining 
neuropeptide release from single cells. Several methods utilizing CE and solid-phase extraction 
(SPE) coupled with MALDI-TOF MS have been used to successfully detect neuropeptide 
secretion from a single neuron (Chen and Lillard, 2001; Rubakhin et al., 2001). The detection of 
activity-dependent release from individual neurons is a desirable method of characterizing 
neuropeptides. Another innovative approach has been the use of micrometer-sized SPE beads 
that can be placed in a specific location of a cell or structure and then analyzed using offline 
MALDI MS (Hatcher et al., 2005). Figure 2.1 shows an application of this technique for the 
collection of neuropeptide release from a single Aplysia californica bag cell neuron. Further 
advances in cellular sampling have led to the development of methods to analyze neuropeptide 
release in various brain subcellular fractions. For example, Fuller & Arriaga (2003) developed a 
method to separate organelles and nuclei and analyze the release of their contents using CE. We 
developed a novel sampling technique coupled to LC-MALDI MS to analyze neuropeptide 
release from KCl-stimulated synaptoneurosomal preparations (Figure 2.2A, B) (Annangudi et 
al., 2010). More recently, advances in the field of microfluidics have enabled one to control the 
neuronal environment and measure peptide release from single neurons when coupled with MS 
instrumentation (Croushore and Sweedler, 2013; Guo et al., 2013). Microfluidic devices offer 
highly regulated conditions and allow high throughput analyses that are difficult to implement 
with other methods.  
Overall, the aforementioned approaches to analyzing neuropeptide release from neuronal 
cells and preparations can enable direct characterization of peptides released from a neuron or set 
of neurons. However, one of the major disadvantages of neuropeptide characterization from 
individual cells is that they do not allow us gain insight into the functioning of neuronal networks 
in vivo. Intact tissue sampling of nervous tissue, however, can provide a more global approach to 
sampling and characterizing neuropeptide release. 
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2.4.2 Intact Tissue Methods 
The characterization of neuropeptides from brain tissue provides additional spatial and 
temporal information that could not otherwise be provided using the aforementioned cellular 
approaches. In addition, physiological levels of neuropeptide release can be observed. Recently, 
methods coupled with MS detection have been developed to analyze release from ex vivo brain 
slices. Hatcher et al. (2008) developed an ex vivo sampling method integrated with MALDI-TOF 
MS to analyze neuropeptide release from the suprachiasmatic nucleus (SCN) (Figure 2.3). A 
specialized tissue chamber provided the optimal environment for maintaining a living brain slice. 
C18 ZipTip pipette tips (Millipore) were positioned directly over the SCN and liquid was drawn 
into the tips, allowing for the collection of extracellular releasate for analysis using MALDI-TOF 
MS. This method, which can be used to analyze releasates from localized brain regions, allowed 
us to demonstrate that the mouse model of Fragile X syndrome has reduced neuropeptide release 
in the cerebral cortex and SCN (Annangudi et al., 2010). Fournier et al. (2003) implemented a 
similar technique using MALDI MS to directly collect neuropeptides from the supraoptic 
nucleus in rat brain slices. In another on-tissue approach, extracellular releasates from ex vivo 
brain slices were collected with a particle-embedded monolithic capillary using a poly(stearyl 
methacrylate-co-ethylene glycol dimethacrylate) monolith (Fan et al., 2011). Fourier transform 
MS has also been shown to be successfully used in conjunction with an ex vivo technique to 
analyze neuropeptide release directly from neuroendocrine tissue of Cancer borealis, or the 
Jonah crab (Kutz et al., 2004). All in all, analyzing neuropeptide release ex vivo from a brain 
slice allows one to bridge single cell and cultured neuron experiments with the in vivo analysis of 
neuropeptides, allowing for real-time sampling in a live animal. 
 
2.4.3 In-Vivo Method 
Approaches using in vivo sampling techniques coupled to analytical methods are critical 
in the field of peptidomics. They allow for real-time collection of analytes, while still utilizing 
well-known CE, LC, and MS approaches for data acquisition. One sampling technique that has 
been widely used in conjunction with analytical methods is microdialysis, which allows for 
continuous collection with minimal disturbance of the physiological system (Davies et al., 2000). 
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In microdialysis, a probe containing a dialysis membrane is inserted into the tissue of interest to 
collect samples, while an isotonic solution is pumped through the probe, allowing for the 
exchange of analytes with the extracellular fluid. Past innovations using CE for in vivo 
microdialysis coupled with the use of a quadrupole ion trap mass spectrometer have improved 
the sensitivity of detection for the small analyte concentrations typically acquired from 
microdialysis (Haskins et al., 2004; Haskins et al., 2001; Kennedy et al., 2002). As outlined in 
other chapters, LC is an effective technique for the online analysis of microdialysis samples. In 
LC, the temporal resolution of the sample analysis can be manipulated by adjusting the flow rate 
of separation (Davies et al., 2000), assuming the samples have sufficient analytes to characterize. 
A drawback of LC can be sample losses, as injection is not continuous. Several groups have 
reported innovative solutions to overcome this challenge. Steele and Lunte (1995) developed 
multiple sample loops to allow for the continuous flow of microdialysate, which they used to 
examine the pharmacokinetics of acetaminophen in rats. Additionally, Leggas et al. (2004) 
created a method that involved an online injector, used to probe rat cerebrospinal fluid for 
pharmacokinetic analysis. Recent advances in SPE-LC MS have resulted in higher analyte 
concentrations and better throughput, even with smaller sample volumes (Gode et al., 2012; Yan 
et al., 2009). Furthermore, LC-MS has been documented for the in vivo analysis of transmitters 
such as acetylcholine from rat brain (Keski Rahkonen et al., 2007). NanoESI-MS has been used 
for the online analysis of in vivo microdialysis samples (Jakubowski et al., 2005). Because of the 
low levels of neuropeptides compared to classical transmitters, its widespread application for 
non-targeted neuropeptide studies has been fairly rare. 
The progress in offline analyses of in vivo microdialysis sampling by MS is noteworthy. 
The offline approaches allow the detection process to be optimized independent of the sampling, 
but reduce the direct link between sampling and measurement.  A thermospray ionization source 
was one of the first offline MS systems to be used for the analysis of microdialysis samples, 
specifically, for monitoring the time course of an experimental drug in the nucleus accumbens of 
rat (Menacherry and Justice, 1990). One of the challenges of using MS in microdialysis is the 
high salt content in the microdialysate, which can negatively impact the MS detection process. 
SPE is a well-utilized method of removing salts from microdialysate for offline analysis, as 
shown by Prokai et al. (1998). Recently, our group developed a similar approach for collecting 
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and conditioning samples using SPE via pre-equilibrated C18 ZipTip pipette tips, which allow 
for peptide concentration and removal of salts from microdialysate (Figure 2.4A). We have 
utilized ZipTips for the direct collection of in vivo microdialysate samples coupled with MALDI-
MS to characterize extracellular peptide release from the ventral hippocampus of rats in response 
to saline or morphine injection (Figure 2.4B). Microdialysis probes are inserted into the 
hippocampus of freely-moving rats, microdialysate is collected directly into ZipTip pipette tips 
in line with the perfusate output, and then directly spotted onto a MALDI target after which 
several released peptides are detected. Although these techniques are a great tool for analyzing 
samples in a physiological setting, limitations can include difficulty of working with delicate and 
complex tissues/animals, limited temporal and spatial resolution, and low in vivo concentrations 
of analytes (Perry et al., 2009). Overall, combining the sensitivity of well-known analytical 
methods with in vivo microdialysis sampling provides a powerful toolset that has great potential 
for advancing the field of peptidomics. 
 
2.5 Conclusions 
Recent advances in the technologies used to characterize neuropeptides have helped 
propel the field of neuropeptide research to new levels with the discovery of greater numbers of 
peptides from ever smaller tissue samples. Single cell analysis offers an innovative means of 
using in vitro sampling to provide localized and neuron-specific peptide information. Over this 
past decade, the ability to characterize peptides has enabled scientists to characterize thousands 
of brain peptides. However, little information exists on whether these newly discovered peptides 
function as cell to cell signaling molecules.   
Besides peptide complements, approaches for neuropeptide release measurements are 
important. The development of ex vivo methods for analyzing neuropeptide release from slices 
and cultured cells and tissues has provided important additional functional information.  There 
has also been a great deal of progress in the development of both online and offline systems for 
in vivo microdialysis methods for characterizing peptide release directly from the brain, offering 
real-time sampling from live animals. Adding the dimension of measuring peptide release 
provides a critical functional context important in determining which of these act as 
neuropeptides or hormones.  
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Optimized sampling protocols and newer instrumental enhancements allow peptide 
release measurements with improved spatial and temporal resolution. Using such approaches, 
analysts provide a physiological context to the characterization of neuropeptides and perhaps 
more importantly, enhance our understanding of their functions. 
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2.6 Figures 
 
 
Figure 2.1 Single-bead SPE collection coupled with MALDI MS to analyze neuropeptide 
release from a single Aplysia californica bag cell neuron. (A) Localization of SPE beads (arrows) 
on neuronal processes of a cultured bag cell neuron. (B) Action potentials in cultured bag cell 
neurons obtained with 4 nA of depolarizing current. (C) Mass spectra from single SPE bead 
releasates (i) before, (ii) during, and (iii) after stimulation. A characteristic mass spectrum of 
acidic peptide confirms the identity of a (iv) cultured bag cell neuron. Reprinted with permission 
from Hatcher et al., 2005. Copyright © 2005 by American Chemical Society.  
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Figure 2.2 Collection of releasates from synaptoneurosomal preparations coupled to LC-MALDI 
MS. (A) Schematic work-flow of the preparation of samples for analysis. (B) Mass profiles from 
releasates of (a-b) WT synaptoneurosomes show a number of high intensity peaks compared to 
the (c-d) Fmr1 KO synaptoneurosomes. MS/MS analysis or accurate mass match was used to 
identify peaks as peptides derived from (i) PEP-19, (ii) cholecystokinin 12, (iii) unknown m/z 
1776.7, (iv) unknown m/z 1923.7, (v) stathmin (vi) orexin B, (vii) unknown m/z 3387.0, (viii) 
thymosin β4, (ix) thymosin β10. Inset shows an expanded mass region from the fraction 
containing stathmin peptide at m/z 2348.2. Adapted and reprinted with permission from 
Annangudi et al., 2010. Copyright © 2010 by American Chemical Society. 
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Figure 2.3 Analysis of neuropeptide release from an ex vivo brain slice containing the 
suprachiasmatic nucleus (SCN). Experimental set-up includes obtaining a sagittal brain slice, 
incubating in brain slice chamber, collecting releasates with a ZipTip pipette tip placed on the 
SCN, de-salting, and characterizing analytes with MALDI MS. Reprinted with permission from 
Hatcher et al., 2008. Copyright © 2008 by Proceedings of the National Academy of Science. 
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Figure 2.4 In vivo microdialysis coupled to MALDI MS to analyze extracellular releasate from 
hippocampi of awake and freely-moving rats. (A) Schematic work-flow of obtaining data from in 
vivo microdialysis. (B) Set-up of fluorinated ethylene propylene (FEP) tubing and C18 ZipTip 
pipette tips in line with perfusate output for collection of microdialysate from left and right 
ventral hippocampi. (C) MALDI MS spectrum showing peaks with m/z 1738.80 and m/z 
1667.76, corresponding to fibrinopeptide A and fibrinopeptide A-derived peptide, respectively, 
detected at high levels from microdialysis collections.  
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CHAPTER 3 
 
NEUROPEPTIDE RELEASE IS IMPAIRED IN   
A MOUSE MODEL OF FRAGILE X SYNDROME 
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Health (NIMH) under Award No. MH035321.  
 
3.2 Abstract 
Fragile X syndrome (FXS), an inherited disorder characterized by mental retardation and 
autism-like behaviors, is caused by the failure to transcribe the gene for fragile X mental 
retardation protein (FMRP), a translational regulator and transporter of select mRNAs. FXS 
model mice (Fmr1 KO mice) exhibit impaired neuropeptide release. Release of biogenic amines 
does not differ between wild-type (WT) and Fmr1 KO mice. Rab3A, an mRNA cargo of FMRP 
involved in the recruitment of vesicles, is decreased by ~50% in synaptoneurosomes of Fmr1 
KO mice; however, the number of dense-core vesicles (DCVs) does not differ between WT and 
Fmr1 KO mice. Therefore, deficits associated with FXS may reflect this aberrant vesicle release, 
specifically involving docking and fusion of peptidergic DCVs, and may lead to defective 
maturation/maintenance of synaptic connections. 
 
3.3 Introduction 
Fragile X syndrome (FXS) is the most common cause of inherited mental retardation, 
with an incidence of 1 in 4000 males and 1 in 8000 females (Turner et al., 1996). The molecular 
mechanism underlying FXS involves the expansion of an unstable polymorphic CGG triplet 
repeat to > 200 in the 5' untranslated region of the Fmr1 gene (Fu et al., 1991; Oberle et al., 
1991). This results in hypermethylation of the Fmr1 promoter and silencing of the Fmr1 gene, 
with consequent absence of the protein product, fragile X mental retardation protein (FMRP) 
(Oberle et al., 1991). FMRP is an mRNA-binding protein that is enriched at the synapse and 
known to regulate the transport and localized translation of mRNA in response to mGluR 
receptor activation (Dictenberg et al., 2008). Many of the mRNA cargoes associated with FMRP 
encode proteins crucial for spine maturation and synaptic plasticity (Brown et al., 2001; 
Miyashiro et al., 2003; Dolen et al., 2007; Hayashi et al., 2007). 
 In the absence of FMRP, there is defective regulation of localized mRNA translation. 
This absence affects synaptic plasticity in FXS, with abnormalities in long-term potentiation 
(LTP) and long-term depression (LTD) (Godfraind et al., 1996; Huber et al., 2002) in Fmr1 
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knockout (KO) mice, which exhibit characteristics of FXS (Consortium et al., 1994; Irwin et al., 
2000). The absence of FMRP should lead to dysregulated local protein levels in both axons and 
dendrites, but previous reports have focused largely on translational regulation deficits at the 
postsynaptic site in FXS. Studies by Hanson and Madison (2007) and Lauterborn et al. (2007) 
recently suggested possible presynaptic effects caused by the loss of FMRP, prompting us to 
examine neuropeptide release in FXS. The mRNA cargoes of FMRP include presynaptic 
proteins that participate in the secretory pathway, in particular, vesicle exocytosis (Brown et al., 
2001; Miyashiro et al., 2003). One such protein is Rab3A, a GTPase that cycles between a 
soluble Rab3A-GDP form and a vesicle membrane-bound Rab3A-GTP form, and which is 
involved in activity-dependent vesicle docking and fusion at the synapse (Geppert et al., 1997; 
Leenders et al., 2001). Changes in Rab3A levels would be expected to affect activity-dependent 
release of transmitters and modulators. Using Western blot analyses, we characterized the levels 
of this protein in wild-type (WT) and Fmr1 KO mice.  
 Next, we used matrix-assisted laser desorption/ionization (MALDI) mass spectrometry 
(MS) to examine synaptoneurosomal preparations and probed the physiology of stimulus-evoked 
neuropeptide release in Fmr1 KO mice using live brain slices. Our results indicate that these 
mice are markedly deficient in neuropeptide release. In order to determine whether the 
neuropeptide release deficit in Fmr1 KO mice is a general deficit in dense-core vesicle (DCV) 
release, we used electrochemistry to examine the release of biogenic amines. We show that the 
release deficit is specific to peptides, as there is no significant difference in the release of 
dopamine (DA), serotonin (5-HT), and norepinephrine (NE) from the striatum of WT and Fmr1 
KO mice. Lastly, using electron microscopy to quantify the number of peptide-housing DCVs, 
we do not observe significant differences between WT and Fmr1 KO mice, again suggesting a 
specific release deficit in FXS. 
 
3.4 Results and Discussion 
3.4.1 Levels of Rab3A in WT and Fmr1 KO Mouse Brains 
We characterized the amount of Rab3A at the synapse using synaptoneurosomal 
preparations, which are enriched in intact pinched-off synaptic processes, from postnatal 10–14 
(P10–14) WT and Fmr1 KO mice. Using Western blot analysis, we found Rab3A expression to 
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be reduced by ~50% in isolated cortical synapses of Fmr1 KO mice (n = 8) compared with WT 
(n = 8; p < 0.01) (Figure 3.1A, B). The amount of Rab3A in total cortical homogenates was also 
decreased in the Fmr1 KO mice, however, to a smaller extent, because total homogenates 
contain more somatic material (Figure 3.1C, n = 4, WT; n = 4, Fmr1 KO; p < 0.01). 
The decrease in Rab3A may be accompanied by a decrease in Rab3 interacting proteins. Liao 
et al. (2008)  recently reported reduced protein levels of other Rab isoforms in Fmr1 KO mice, 
including several proteins involved in vesicle exocytosis. Rab3A KO mice have previously been 
shown to have altered activity-dependent vesicle release (Geppert et al., 1997) and complete loss 
of LTP at the hippocampal CA3 mossy fiber synapses (Castillo et al., 1997). Although the 
mechanism behind Rab3A function in FXS is currently unknown, we speculate that there may be 
an imbalance in Rab3A-GDP and Rab3A-GTP cycling. It has previously been shown that an 
accumulation of membrane-bound Rab3A-GTP leads to a reduction in docked DCVs (Sakane et 
al., 2006). Van Weering et al. (2007) have observed that neither Rab3A-GTP- nor Rab3A-GDP-
locked mutant chromaffin cells exhibited any differences in the total amount of DCVs as 
compared to WT chromaffin cells. To examine the cycling of Rab3A in Fmr1 KO mice, 
subcellular fractions (Hallett et al., 2008) containing Rab3A-GDP and Rab3A-GTP were blotted 
for Rab3A expression to examine the possibility that there is a cellular sorting defect in Rab3A 
expression. Western blotting for Rab3A in P3 (membrane) and S3 (cytosolic) fractions revealed 
that there are no significant differences between the sorting of Rab3A in Fmr1 KO and WT brain 
(Figure 3.2). Further study is needed to elucidate a more detailed mechanism of this defect.   
 
3.4.2 Neuropeptide Release 
To directly investigate if there is a peptide release deficit associated with reduced Rab3A, 
we developed an MS-based protocol to examine stimulation-dependent release of peptides from 
WT and Fmr1 KO mouse cortical synaptoneurosomes. Previously reported methods primarily 
used electrophysiology to observe the effects of stimulation at Fmr1 KO mouse synapses 
(Wilson and Cox, 2007). Synaptosomes have been used for many studies on neurotransmitter 
release (Ghijsen et al., 2003). Here, we adapted small-volume (Rubakhin et al., 2006; Rubakhin 
and Sweedler, 2007) and neuropeptide release collection approaches (Hatcher et al., 2005; Jing et 
al., 2007; Hatcher et al., 2008; Hatcher and Sweedler, 2008) to enable MS-based peptide 
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characterization of released peptides in Fmr1 KO mice. Briefly, synaptoneurosomal preparations 
from WT and Fmr1 KO mice (n = 4, WT; n = 5, Fmr1 KO) were stimulated with KCl (55 mM), 
and the releasates were concentrated and separated into fractions using reversed-phase liquid 
chromatography (LC). The fractions were analyzed using MALDI-MS. The resulting mass 
profiles of releasates from WT cortical synaptoneurosomes revealed stimulation-dependent 
release of several peptide signaling molecules as well as protein fragments (Figure 3.3A). Little 
or no stimulated peptide release was observed in cortical synaptoneurosomes from Fmr1 KO 
mice; the reduction in peptide release is at least 90% and perhaps greater (Figure 3.3C), with the 
large decrease making quantitative measures of decrease difficult. To consider whether the KCl 
stimulation data reflect presynaptic or postsynaptic peptide release events, (S)-3,5-
dihydroxyphenylglycine (DHPG) was administered to stimulate postsynaptic group I 
metabotropic glutamate receptors in the WT synaptoneurosomes; this stimulation did not elicit 
synaptic peptide release. Thus, we suggest, but have not yet fully confirmed, that this deficit is 
presynaptic in nature. Several peptides and protein fragments observed in the releasates of 
stimulated WT synaptoneurosomes were present in sufficient amounts to confirm their identity 
with tandem MS (MS/MS) analysis. These peptides are primarily derived from structural and 
related proteins (such as actin, tubulin and stathmin) and neuropeptide prohormones (Table 3.1).  
To confirm changes in the stimulation-induced release in a more intact preparation, we 
used brain slices obtained from P10–15 WT and Fmr1 KO mice, as described earlier (Hatcher et 
al., 2008). We chose two regions to study: (1) the cerebral cortex, as this was the source of our 
synaptoneurosomes, and (2) the suprachiasmatic nucleus (SCN), a well-defined nucleus that is 
highly peptidergic and for which we previously characterized robust peptide release (Hatcher et 
al., 2008). Using an on-tissue collection strategy, we collected releasates from the cortex and 
SCN of WT and Fmr1 KO mice using a micropipette tip packed with C18 solid-phase extraction 
beads. We then performed MALDI-MS analysis on releasates obtained before and after 
stimulation with 55 mM KCl. The MS profiles showed a significant increase in the number and 
intensity of peaks detected in releasates after stimulation of WT, but not KO slices, compared to 
the pre-stimulated collections (Figure 3.4, n = 4, WT; n = 4, Fmr1 KO). In addition to arginine 
vasopressin, somatostatin, and proSAAS, which have been shown earlier to be released from the 
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SCN (Hatcher et al., 2008), we identified several peptides from the cortex that were also 
identified from the synaptoneurosomal releasates. 
Although we have shown that the impaired release mechanisms are peptide-specific, it is 
reasonable to speculate that other regulated release pathways might be affected, such as cytokine 
and growth factor release. For example, brain-derived neurotrophic factor (BDNF) release from 
CA3 neurons was shown to recruit a presynaptic component of plasticity (Zakharenko et al., 
2003). Lauterborn et al. (2007) recently showed that the LTP deficiency observed in the 
hippocampal field CA1 of Fmr1 KO mice can be rescued by exogenous application of BDNF, 
even though there was no significant difference in the basal level of BDNF in homogenates of 
Fmr1 KO versus WT hippocampus; therefore, those results also imply a deficit in BDNF 
synaptic release in FXS. 
 
3.4.3 Biogenic Amine Release in Brain Slices 
To analyze the specificity of the observed release deficit, we used electrochemistry-based 
measurements to analyze the stimulus-evoked release of biogenic amines. Brain slices from P70 
WT and Fmr1 KO mice, containing the caudate putamen (CP), ventral bed nucleus of the stria 
terminalis (vBNST), or substantia nigra pars reticulata (SNr), were used to analyze the 
electrically-stimulated release of DA, NE, and 5-HT, respectively, because these particular 
regions are enriched in these biogenic amines (Bunin et al., 1998; Miles et al., 2002; Johnson et 
al., 2006). DA release in striatal brain slices was evoked by a single-pulse electrical stimulation 
(Figure 3.5A). Stimulated release of 5-HT (20 pulses at 20 Hz) in slices of the SNr had a similar 
profile; however, the maximal release values and rate of uptake are both lower than that seen for 
DA (Figure 3.5B). NE release was evoked by 60 pulses at 60 Hz stimulation and demonstrated 
the slowest uptake of all three neurotransmitters (Figure 3.5C). Electrically-stimulated DA 
release monitored by fast-scan cyclic voltammetry was unchanged in Fmr1 KO mice when 
compared to WT mice ( n = 6, WT; n = 7, Fmr1 KO; p > 0.05).  Additionally, NE release in the 
vBNST stimulation was not different (n = 4, WT; n = 6, Fmr1 KO; p > 0.05) between Fmr1 KO 
and WT control animals. This trend was repeated in the SNr where stimulation evoked the same 
amount of 5-HT in both animals (n = 6, WT; n = 7, Fmr1 KO; p > 0.05). Similar results were 
found when monitoring exocytosis from chromaffin cells (Figure 3.6 and Table 3.2). The lack 
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of differences in release of biogenic amines between WT and Fmr1 KO mice shows that the 
presynaptic release deficit is not general but is transmitter specific. 
 
3.4.4 Quantification of Dense-Core Vesicles 
It is known that both clear-core vesicles, which house many classical neurotransmitters, 
and large DCVs, which house peptides and perhaps the catecholamines, are mobilized and 
released in an activity-dependent manner (Torrealba and Carrasco, 2004; Shakiryanova et al., 
2005). Because DCVs contain neuropeptides, we considered whether the decrease in the amount 
of peptides observed in Fmr1 KO mice was due to a decrease in the number of DCVs. We 
examined electron micrographs containing layer IV of the visual cortex from P15 and P25 WT 
and Fmr1 KO mice, utilizing unbiased stereological methods to look for differences in the 
density of DCVs (DCVs/μm3). While a decrease in DCVs/μm3 between WT and Fmr1 KO mice 
at both P15 and P25 was observed (Figure 3.7), these differences did not reach significance. A 
significant decrease in DCVs/μm3 from P15 to P25 was observed for both genotypes. 
Specifically, our analysis revealed a main effect of age (p < 0.01), but no main effect of genotype 
(p = 0.220) and no genotype*age interaction (p = 0.996).  
 
3.5 Conclusions 
MS-based assays that are capable of analyzing release enable characterization of peptide 
secretion following chemical stimulation, without having to preselect the peptides (Hatcher et al., 
2005; Hatcher et al., 2008; Li and Sweedler, 2008). The ability to collect and characterize 
peptide release allows us to present the first report of impaired peptidergic release in the FXS 
mouse model. Although there is not a significant reduction of DCVs in FXS, there is a ~50% 
reduction in synaptic levels of Rab3A. These results suggest that some of the deficits in Fmr1 
KO mice may be directly correlated with deficits in the peptide release machinery. Intriguingly, 
the release deficit observed in the Fmr1 KO mice involves the release of neuropeptides in the 
neocortex and does not involve biogenic amines in the striatum, suggesting a deficit in the 
release of peptidergic DCVs, at least in several brain regions of FXS mice. Because similar 
reductions in peptide release are observed in both functional synapses (synaptoneurosomes) and 
in brain slices from the cerebral cortex and the SCN, this impairment appears to be fairly general 
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and may be associated with synaptic machinery, perhaps aberrant DCV docking and fusion, in 
which Rab3A normally participates. Stimulated release of DA, NE, and 5-HT is unaffected in the 
striatum, and basal synaptic transmission in Fmr1 KO mice is similar to WT mice (Zhao et al., 
2005), results that point to a specific release defect in the brain. 
In conclusion, there appears to be a role for cell-to-cell signaling in the etiology of FXS, 
possibly affecting one or more phases of the synaptogenesis and synaptic stabilization sequence 
(Vaughn, 1989; Ziv and Garner, 2004). Peptides characterized as released from the synapses in 
an activity-dependent manner include fragments of structural proteins such as actin, tubulin and 
stathmin, which are involved in exocytosis. Their dynamics play a role in the morphological 
plasticity of dendritic spines (Fischer et al., 1998), and release of these peptides is reduced in 
Fmr1 KO mice. The resilience of this defect, as observed in synaptoneurosomes and slice 
preparations from several brain regions, suggests that this impaired peptide-specific release may 
be a fundamental biological deficit, and may contribute to defective synaptic 
maturation/maintenance and the behavioral deficits known to be associated with FXS. The 
correlation between FXS and the neuropeptide release deficit suggests that this is a unique 
pharmacological target, which, if restored, may ameliorate some of the effects of FXS. 
 
3.6 Methods 
3.6.1 Animals 
WT and sighted Fmr1 KO mice bred in the FVB.129P2-Fmr1
tm1Cgr  
background were 
housed at the Beckman Institute at the University of Illinois at Urbana-Champaign (UIUC) or the 
University of North Carolina at Chapel Hill (UNC-CH) animal facility. Mice were maintained 
under controlled environmental conditions, with standard alternating periods of 12-h light and 
darkness. Rodent chow and water were provided ad libitum. Animal care and procedures in 
accordance with the National Institutes of Health regulations and protocols were approved by the 
UIUC and UNC-CH Institutional Animal Care and Use Committees. 
 
3.6.2 Synaptoneurosomal and Total Cortical Homogenate Preparation 
  Synaptoneurosomes were prepared from cortices of P10–14 WT and Fmr1 KO mice. For 
the MS measurements of synaptoneurosome release only, six experiments were performed using 
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rat cortices to validate our ability to stimulate peptides and collect releasates (n = 6). Once the 
ability to collect peptide release was shown to be robust, we modified the procedures for smaller 
mouse samples. Briefly, mice were sacrificed by decapitation. Brains were removed
 
and 
dissected, and several cerebral cortices pooled to obtain adequate cellular material for each 
experiment (n = 4, WT; n = 5, Fmr1 KO with each sample consisting of two or three cortices). 
Cortices were homogenized in a glass-Teflon
 
homogenizer in 1 mL of ice-cold homogenizing 
buffer (50 mM HEPES, pH
 
7.5, 125 mM NaCl, 100 mM sucrose, 2 mM potassium acetate), 
filtered
 
through a series of nylon mesh filters (149, 62, 30 and 10 µm;
 
Small Parts, Inc.) and 
finally through a 10-µm polypropylene
 
filter (Gelman Sciences, Ann Arbor, MI). Filters were 
washed at each step with
 
the ice-cold homogenizing buffer. The final filtrate
 
was spun briefly 
(4,000 × g, 4 °C, 1 min) to remove cellular debris; final supernatant volume
 
was ~1 mL. This 
synaptoneurosomal preparation was either used directly for stimulation and collection of 
releasates by MS or was lysed (for Western blot analysis) in a lysis buffer [final concentration 50 
mM Tris (pH 8), 150
 
mM NaCl, 1% Nonidet P-40, 20 nM okadaic acid, 20 µM sodium
 
orthovanadate, phosphatase inhibitor mixture (Pierce, Rockford, IL), and protease
 
inhibitor 
mixture (Roche, Indianapolis, IN)]. NP-40 soluble total cortical homogenate was prepared in the 
following way: cortices from a single mouse, P10–14, were homogenized in NP-40 lysis buffer 
[final concentration 50 mM Tris (pH 8), 150
 
mM NaCl, 1% Nonidet P-40, 20 nM okadaic acid, 
20 µM sodium
 
orthovanadate, phosphatase inhibitor mixture (Pierce), and protease
 
inhibitor 
mixture (Roche)], spun (15,000 × g, 4° C, 15 min), and then the supernatant was collected.  
 
3.6.3 Western Blot Analysis 
For each synaptoneurosomal preparation and total cortical homogenate sample, 30 µg of 
lysed protein samples were run
 
on 12% polyacrylamide gels, blotted to nitrocellulose 
membranes,
 
and stained with rabbit polyclonal antibody specific for Rab3A
 
(Abcam, Cambridge, 
MA). HRP-labeled secondary anti-rabbit
 
antibody (Cell Signaling Technology, Inc., Danvers, 
MA) was detected by enhanced chemiluminescence
 
(Pierce). To quantify and standardize protein 
levels, blots were stained for β-actin (Sigma Aldrich, St. Louis, MO) and with Amido Black (J. 
T. Baker, Phillipsburg, NJ) for total protein.
 
Chemiluminescence was scanned in a FluorChem 
8900 Imager (Alpha
 
Innotech, San Leandro, CA) and relative optical densities were determined 
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by
 
using AlphaEaseFC software, version 4.0.1 (Alpha Innotech),
 normalized to β-actin level and 
total protein loaded. 
 
3.6.4 Synaptoneurosomal Stimulation 
The synaptoneurosomal preparations, obtained from two to three mouse cerebral cortices 
for each preparation, were divided into two equal aliquots used as a control (unstimulated) or as 
the stimulated sample. For the stimulated samples, 1 M of KCl (55 mM final concentration), or 1 
M of DHPG (Tocris Cookson, Ellisville, MO; 5 mM final concentration), was added to one of 
the aliquots and incubated for 15 min. For the control samples, 50 µL of homogenizing buffer 
was added. After stimulation, the aliquots were centrifuged (4
 
min at 4,000 × g at 4 °C) and the 
supernatant was collected. The peptides present in the supernatant were desalted and 
concentrated using a spin-column (Pierce) according to the manufacturer’s protocols. These 
measurements were repeated for 9 samples (from 21 animals). In two instances, after chemical 
stimulation, no peptides (including the normally ubiquitous β-thymosin) were detected via MS, 
indicating an issue with the preparation; in such cases, the data were excluded.  
 
3.6.5 Brain Slice Preparation and Stimulation 
Brain slices were prepared from P10–P15 WT and Fmr1 KO mice. Briefly, mice were 
quickly decapitated, brains were removed
 
and a Vibratome (Vibratome 3000 Series; Ted Pella, 
Redding,CA) was used to obtain 400-µm sections. The sections were placed into a brain slice 
chamber (AutoMate Scientific, Inc., Berkeley, CA) equipped with a proportional temperature 
controller. Each slice was perfused with EBSS (without phenol red), supplemented with 24.6 
mM of glucose, 26.2 mM of NaHCO3, and 2.5 mg/l of gentamycin and saturated with 95% 
O2/5% CO2 at 37 °C, pH 7.4. Collection of releasates from each slice (n = 4, WT; n = 4, Fmr1 
KO) was performed as described earlier (Hatcher et al., 2008) and analyzed by MALDI-MS. 
 
3.6.6 Liquid Chromatography 
The synaptoneurosomal releasates were separated using a capLC™ system (Micromass, 
UK) coupled to a robotic spotter (Proteineerfc™, Bruker Daltonics, Billerica, MA). Briefly, the 
samples were initially loaded onto a 5-µL loop using a manual injector (VALCO Instruments Co. 
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Inc., Houston, TX) and subsequently trapped onto a reversed-phase trap column (PepMap™, 
C18, 5 µm, 100 Å, LC Packings, a Dionex Company, Sunnyvale, CA) using solvent C (90% 
water, 10% acetonitrile (ACN), 0.1% FA and 0.01% trifluoroacetic acid (TFA)) at a flow rate of 
8 µL/min and washed for 5 min. Each sample was then eluted and separated on a reversed-phase 
column (LC Packings™ 300-µm i.d. × 15 cm, C18 PepMap100, 100 Å) using a gradient at 2 
µL/min flow rate for 45 min. Gradients were generated using solvent A (95% water, 5% ACN, 
0.1% TFA) and solvent B (95% ACN, 5% water, 0.1% formic acid and 0.01% TFA). Gradients 
were changed linearly in three different steps; 5–30% solvent B in 15 min, 30–80% solvent B in 
35 min, 80–5% solvent B in 40 min. The chromatographic profile was monitored using a UV 
detector at 210 nm. The capLC system was connected online to the Proteineerfc™ spotter to 
collect the fractions onto a MALDI target. Prior to spotting the fractions, the Proteineerfc was 
programmed to deposit 1 µL of α-cyano-4-hydroxy cinnamic acid MALDI matrix (10 mg/mL, 
60% aqueous ACN, 0.1% TFA). For each sample, a total of 24 fractions were collected at 1 min 
intervals, corresponding to samples eluted from 18–42 min of the chromatographic run. 
 
3.6.7 Mass Spectrometry 
Mass spectrometric analysis of the samples was performed using a MALDI-TOF/TOF 
mass spectrometer (Ultraflex II, Bruker Daltonics). The instrument was externally calibrated 
using a mixture of standard peptides (angiotensin II, angiotensin I, substance P, bombesin, 
ACTH clip 1-17, ACTH clip 18-39, somatostatin 28, bradykinin fragment 1-7, renin substrate 
tetradecapeptide porcine) in the mass range 700–3200 Da (Bruker Daltonics).  For each of the 
synaptoneurosomal releasate fractions, data was collected using 400 laser shots in 10 short steps 
by panning across the spot and combining the spectra. Following data collection, the mass 
spectra were smoothed and baseline corrected and the peaks with high peak intensity and 
signal/noise ratio were tabulated. Releasates from the slice were directly analyzed using 
MALDI-MS. 
MS/MS of selected molecular ion species was performed using the TOF/TOF feature of 
the Bruker Ultraflex II instrument. The MS/MS spectra were processed using FlexAnalysis 2.4 
and Biotools 3.0 software packages (Bruker Daltonics). Partial de novo analysis was also 
performed on the MS/MS spectra using Peaks software (Bioinformatics Solutions Inc., Waterloo, 
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Ontario, Canada) to assist in peptide identification. For the release of peptides from the SCN, 
previously sequenced peptides characterized in the SCN and supraoptic nucleus were used for 
peptide identification (Bora et al., 2008; Hatcher et al., 2008). 
 
3.6.8 Electron Microscopy and DCV Quantification 
Eight P15 WT and ten P15 Fmr1 KO mice, and eight P25 WT and ten P25 Fmr1 KO 
mice were used to analyze DCV quantity in layer IV of the visual cortex. Perfusion and tissue 
preparation procedures for transmission electron microscopy ultrastructural analyses of brain 
have been described in a previous report (Greenough et al., 2001). Within layer IV of the visual 
cortex, a region of neuropil was selected based only on proximity to easily recognizable 
landmarks (capillaries, nuclei, etc.) and on the absence of folds in adjacent sections (aside from 
these two criteria, the region was selected randomly within layer IV). Micrographs from identical 
regions of consecutive (approximately 60-nm thick) serial sections were taken at a magnification 
of 8800× (final magnification 26,400×) by a Phillips CM-200 transmission electron microscope 
and analyzed by raters blind to the experimental group. The density of DCVs was estimated 
using the physical disector (Sterio, 1984), in which disector pairs, composed of a ‘reference’ 
section and a ‘look-up’ section, are analyzed. For each disector pair, the fractionator (Gundersen 
et al., 1988) is used to establish one sampling site that is the area of the electron micrograph in 
layer IV of the visual cortex. Between 6 and 15 serial electron micrographs per tissue block were 
used for stereological analysis. DCVs were characterized by the presence of an electron-dense 
core and at least 50% of circumference surrounded by an intact identifiable double-membrane 
(Umbach et al., 2005); clear-core vesicles were not quantified. The sections were analyzed for 
DCVs present in the reference section but not the look-up section. These DCVs were counted. 
DCVs present on both the reference section and look-up section were not counted. The formulas 
DCVv= Q/Vdis and Vdis = Aframe x T x N were used to obtain DCV density, where DCVv is DCV 
density, Q is the number of DCVs present in the reference section but not the look-up section, 
Vdis is the disector volume of the tissue through which the DCVs are counted, Aframe is the area of 
the superimposed counting frame, T is section thickness, and N is the number of sections through 
which the counting is done.  
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3.6.9 EM Analysis/Statistics 
The SPSS (SPSS Inc., Chicago, IL) statistical package (version 16.0) was used to conduct 
statistical analyses. Independent Student’s t-tests were used to determine statistical significance. 
For DCV quantification, a two-way ANOVA was conducted to determine statistical significance 
for effects of age (P15, P25) and genotype (WT, Fmr1 KO) on 415 micrographs from 36 
animals. For these analyses, p < 0.05 was considered statistically significant. 
 
3.6.10 Electrochemistry 
Chromaffin cells were prepared as previously described (Villanueva et al., 2006; Kolski-
Andreaco et al., 2007).  Plates were maintained in a humidified, 5% CO2 atmosphere at 37 
o
C 
for at least 24 h prior to experimentation. Brain slices were prepared containing the CP (Johnson 
et al., 2006), SNr (Bunin et al., 1998) and BNST (Miles et al., 2002). Slices were superfused in 
aCSF at 37 
o
C for 35–40 min prior to recording. Measurements were made with carbon-fiber 
microelectrodes prepared using T650 carbon fibers (Cahill et al., 1996). At chromaffin cells, 
recordings were made by amperometry with disk electrodes (Villanueva et al., 2006).  
Measurements of DA, NE and 5-HT release in brain slices were made using fast-scan cyclic 
voltammetry at cylindrical electrodes as previously described (Bunin et al., 1998). 
 Exocytosis at chromaffin cells was triggered by 0.5 s pressure ejection of 60 mM K
+ 
 
buffer from a pipette located 30 µm from the cell. Ten stimulations, separated by 30 s, were 
applied to each cell.  In brain slices, release was electrically evoked (Johnson et al., 2006). 
Amperometric spikes were analyzed with MiniAnalysis (Synaptosoft, Decatur, GA). Individual 
amperometric spike characteristics determined were the spike frequency, quantal size (Q), t1/2, 
and amplitude (Colliver et al., 2000). In the slice experiments, the maximal neurotransmitter 
concentrations measured following stimulation are reported.   
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3.7 Figures 
 
 
Figure 3.1 Western blot analysis from P10–14 WT and Fmr1 KO cortical synaptoneurosomes 
and total cortical homogenates shows a reduction in Rab3A expression. (A) Synaptoneurosomal 
lysates from WT and Fmr1 KO cortices were run
 
on 12% polyacrylamide gels, blotted to 
nitrocellulose membranes,
 
and stained with rabbit polyclonal antibody specific for Rab3A, 
followed by antibody to β-actin to normalize to total protein loaded. (B) Rab3A expression in 
Fmr1 KO synaptoneurosomes (n = 8) is dramatically reduced compared to WT (n = 8). Blots 
were normalized to β-actin (β-actin, **, p < 0.01; not shown) and to total protein loaded (**, p < 
0.01; error bars, SEM). (C) Rab3A expression in total cortical homogenates is significantly 
decreased in Fmr1 KO mice, although to a smaller extent than in synaptoneurosomes (n = 4; **, 
p < 0.01).  Adapted and reprinted with permission from Annangudi et al., 2010. Copyright © 
2010 by American Chemical Society. 
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Figure 3.2 No changes in rab3A expression between Fmr1 KO and WT mice in P3 (membrane) 
and S3 fractions (cytosolic). n = 
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Figure 3.3 Synaptoneurosomes from Fmr1 KO mice are defective in neuropeptide release.  LC-
MALDI MS analysis of releasates collected from stimulated (KCl, 55mM) and unstimulated 
(saline) cortical synaptoneurosomes from P10–14 WT and Fmr1 KO mice. Each panel represents 
a profile in the mass range m/z 1300–5000 of several LC fractions for (A, B) WT and (C, D) 
Fmr1 KO mice. The mass profiles obtained from the releasates of stimulated WT 
synaptoneurosomes (a) show a number of high intensity peaks compared to the Fmr1 KO 
synaptoneurosomes (b). Using MS/MS analysis or accurate mass match, several peaks were 
identified as peptides derived from (a) PEP-19, (b) cholecystokinin 12, (c) unknown m/z 1776.7, 
(d) unknown m/z 1923.7, (e) stathmin (f) orexin B, (g) unknown m/z 3387.0, (h) thymosin β4, (i) 
thymosin β10. Inset shows an expanded mass region from the fraction containing stathmin 
peptide at m/z 2348.2. Adapted and reprinted with permission from Annangudi et al., 2010. 
Copyright © 2010 by American Chemical Society. 
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Figure 3.4 Defective neuropeptide release from Fmr1 KO brain slice preparations. MALDI MS 
analysis of releasates from whole brain slices (400 µm) containing SCN and cortex, from P10–15 
WT and Fmr1 KO mice. Slices stimulated with a topical application of 55 mM KCl show 
marked increase in the number and intensity of peptides observed in WT mice compared to Fmr1 
KO mice (n = 4, WT and n = 4, Fmr1 KO). (A) Mass profiles obtained from the cortex and (B) 
from the SCN. Inset in panel a shows relative intensity of neurokinin B and inset in panel B 
shows arginine vasopressin, for all four conditions. Adapted and reprinted with permission from 
Annangudi et al., 2010. Copyright © 2010 by American Chemical Society. 
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Figure 3.5 Biogenic amine (DA, NE, 5-HT) release from WT and Fmr1 KO brain slice 
preparations is not significantly different. (A) DA release in the CP evoked with a single 
stimulus pulse. (B) 5-HT release evoked in the SNr by a 20 pulse 100 Hz stimulation train. (C) 
NE release in the BNST was evoked by a 60 pulse 60 Hz stimulation. Data shown are from WT 
tissues. (D) Identical release concentrations were performed observed in brain slices from WT 
and Fmr1 KO (p > 0.05, n = 6 from each genotype for each neurotransmitter). Adapted and 
reprinted with permission from Annangudi et al., 2010. Copyright © 2010 by American 
Chemical Society. 
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Figure 3.6 Vesicular release events at WT and Fmr1 KO chromaffin cells.  Representative 
amperometric traces measured in response to a 0.5 s stimulation with 60 mM K
+
 at chromaffin 
cells from WT (A) and Fmr1 KO (B) mice.  Adapted and reprinted with permission from 
Annangudi et al., 2010. Copyright © 2010 by American Chemical Society.    
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Figure 3.7 Electron microscopy of layer IV visual cortex of WT and Fmr1 KO mice reveals no 
differences in DCVs/μm3. (A) Representative EM images from P15 WT (upper left), P15 Fmr1 
KO (upper right), P25 WT (lower left) and P25 Fmr1 KO (lower right) mice. DCVs are shown in 
the presynaptic terminal. However, DCVs were counted in all neuropil present on EM image, 
regardless of whether they were in a bouton or not. (B) DCV quantification shows no differences 
in DCVs/μm3 between P15 and P25 WT and Fmr1 KO mice. Two-way ANOVA analysis 
revealed main effect of age was statistically significant (**, p < 0.01; P15 < P25; error bars, 
SEM) for both genotypes. Age: **, p < 0.01  (P15 < P25); Genotype: p = 0.220; 
Genotype*Age: p = 0.996. D, dendrite (the postsynaptic compartment); A, axon (the presynaptic 
terminal). Arrows point to DCV. Adapted and reprinted with permission from Annangudi et al., 
2010. Copyright © 2010 by American Chemical Society.   
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Precursor/protein Detected peptide m/z Sequence 
Angiotensinogen Angiotensin II  1046.58 DRVYIHPF 
Beta-neoendorphin-dynorphin Beta-neoendorphin 1099.62 YGGFLRKYP 
Progonadoliberin-1 Gonadoliberin-1 1198.68 QHWSYGLRPG-amide 
Preprotachykinin B  Neurokinin B 1210.60 DMHDFFVGLM-amide 
Angiotensinogen Angiotensin I  1296.70 DRVYIHPFHL 
Hemoglobin subunit beta-1 LVV-hemorphin-7 1324.71 LVVYPWTQRY 
Tubulin alpha-1A chain Tubulin (53-65) 1356.70 FSETGAGKHVPRA 
Purkinje cell protein 4  PEP-19 (51-62) 1392.82 RKFQKKKAGSQS 
Pro-opiomelanocortin DiAc-MSH fragment 1414.79 Ac-SMEHFRWGKPV-amide  
Tubulin alpha-1A chain Tubulin (53-66) 1455.77 FSETGAGKHVPRAV 
Cholecystokinin Cholecystokinin 12 1534.70 ISDRDYMGWMDF-amide 
Heat shock protein 10 HSP10 (2-14) 1551.10 Ac-AGQAFRKFLPLFD 
Tubulin alpha-1A chain Tubulin (53-67) 1602.82 FSETGAGKHVPRAVF 
Actin beta Actin beta (357-373) 1973.02 ISKQEYDESGPSIVHRK 
Tubulin beta-5 chain Tubulin beta (152-167) 2012.04 ISKIREEYPDRIMNTF 
GAPDH GAPDH (309-325)  2092.92 ISWYDNEYGYSNRVVDL 
Stathmin Stathmin (2-22) 2348.06 ASSDIQVKELEKRASGQAFEL 
Orexin Orexin B 2935.70 RPGPPGLQGRLQRLLQANGNHAAGILTM-amide 
  unknown 1694.01   
  unknown 1807.07   
  unknown 1931.10   
  unknown 2791.60   
  unknown 3387.00   
 
Table 3.1 Peptides identified from stimulated WT synaptoneurosomes. The identifications have been confirmed using tandem MS; 
peptide and protein nomenclature follows www.expasy.org. Adapted and reprinted with permission from Annangudi et al., 2010. 
Copyright © 2010 by American Chemical Society. 
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Cell Type 
Total  
Spikes 
Burst 
Length(s) 
Spike  
Freq (Hz) 
% w/Foot Imax (pA) Q (molecules) t½ (ms) 
WT (n = 53) 310 ± 20 3.4 ± 0.2 8.4 ± 0.3 11.1 ± 0.4 76 ± 4 (8.0 ± 0.4) x 10
5
 5.3 ± 0.2 
Fmr1 KO (n = 43) 320 ± 20 3.5 ± 0.2 9.1 ± 0.4 11.1 ± 0.4 78 ± 4 (8.9 ± 0.6) x 10
5
 5.5 ± 0.2 
 
Table 3.2 Amperometric spike characteristics of vesicular release events at chromaffin cells from WT and Fmr1 KO mice. The 
average number of spikes recorded during a trace (10 stimulations) and the average length of and frequency of spikes within an 
individual burst of exocytosis following a 0.5 s stimulation with 60 mM K
+
 are shown.  Individual spike characteristics, including % 
of events with a foot feature, amplitude (Imax, in pA), quantal size (Q, in molecules of catecholamine), and halfwidth (t1/2, in ms), were 
averaged over the entire trace.  No significant differences were observed between WT and Fmr1 KO cells (p > 0.05, one-way 
ANOVA). Adapted and reprinted with permission from Annangudi et al., 2010. Copyright © 2010 by American Chemical Society. 
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CHAPTER 4 
  
A FIBRINOGEN α-CHAIN-DERIVED PEPTIDE IS UPREGULATED IN 
HIPPOCAMPUS OF RATS EXPOSED TO ACUTE MORPHINE INJECTION  
AND SPONTANEOUS ALTERNATION TESTING 
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4.2 Abstract 
Fibrinogen is a secreted glycoprotein that is synthesized in the liver although recent in 
situ hybridization data support its expression in the brain.  It is involved in blood clotting and is 
released in the brain upon injury. Here, we report changes in the extracellular levels of 
fibrinogen α-chain-derived peptides in the brain after injections of saline and morphine. More 
specifically, in order to assess hippocampus-related working memory, an approach pairing in 
vivo microdialysis with mass spectrometry was used to characterize extracellular peptide release 
from the hippocampus of rats in response to saline or morphine injection coupled with a 
spontaneous alternation task. Two fibrinopeptide A-related peptides derived from the fibrinogen 
α-chain—fibrinopeptide A (ADTGTTSEFIEAGGDIR) and a fibrinopeptide A-derived peptide 
(DTGTTSEFIEAGGDIR)—were shown to be consistently elevated in the hippocampal 
microdialysate. Fibrinopeptide A was significantly upregulated in rats exposed to morphine and 
spontaneous alternation testing compared with rats exposed to saline and spontaneous alternation 
testing (p < 0.001), morphine alone (p < 0.01), or saline alone (p < 0.01), respectively. The 
increase in fibrinopeptide A in rats subjected to morphine and a memory task suggests that a 
complex interaction between fibrinogen and morphine takes place in the hippocampus. 
 
4.3 Introduction 
Fibrinogen is a plasma glycoprotein that is synthesized in the liver, secreted, and stored in 
α-granules of platelets and megakaryocytes (Handagama et al., 1989; Harrison et al., 1989). It is 
part of an extensive biochemical pathway involved in blood clotting and fibrinolysis. Fibrinogen 
is composed of two sets of three polypeptide chains Aα, Bβ, and γ, which are joined by disulfide 
bridges at the N-terminal domain (Henschen et al., 1983; Hoeprich and Doolittle, 1983; Zhang 
and Redman, 1992; Huang et al., 1993). Each Aα-chain contains an N-terminal fibrinopeptide A 
sequence, which is cleaved by thrombin and initiates fibrin assembly (Laudano and Doolittle, 
1980; Liu et al., 1985; Atkins et al., 1993). Fibrinopeptide A is a 17-amino acid peptide that has 
been shown to be an indicator of fibrin assembly/clot formation (Atkins et al., 1993). During 
blood coagulation, fibrinogen gets converted to fibrin by thrombin. Fibrin is then cross-linked 
with factor XIII to form a clot. During fibrinolysis, the opposite occurs; the enzyme plasmin 
(zymogen form is plasminogen) helps dissolve the fibrin clots. Plasmin is activated by a variety 
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of enzymes, such as tissue plasminogen activator (tPA), which binds to fibrin when plasminogen 
is activated (Hoylaerts et al., 1982).  
Fibrinogen has predominantly been reported to be on the blood side of the blood-brain-
barrier and released into the brain upon injury (Adams et al., 2004; Ahn et al., 2010).  However, 
in situ hybridization data from the Allen Mouse Brain Atlas show mRNA expression of 
fibrinogen α-, β-, and γ-chains in mouse brain, with the strongest expression in the hippocampus 
(©2012 Allen Institute for Brain Science. Allen Mouse Brain Atlas [Internet]. Available from: 
http://mouse.brain-map.org; Lein et al., 2007). Furthermore, there are reports of interactions 
between fibrinogen and morphine. Buczko and Wiśniewski (1972) have shown that fibrinogen 
degradation products can potentiate morphine’s analgesic effects. In addition, morphine therapy 
after surgery can lead to increased blood clotting and consequently, arterial thrombosis 
(Rosenfeld et al., 1993). 
While direct studies of a preselected peptide such as fibrinopeptide A use selective 
approaches like immunohistochemistry, mass spectrometry (MS)-based studies allow detection 
of unspecified brain peptides (Chen and Lillard, 2001; Dowell et al., 2006; Li and Sweedler, 
2008; Bernay et al., 2009). Previous investigations using MS have identified hundreds of 
prohormone-derived and other protein-derived peptides in the brain, and a subset of these studies 
have detected fibrinogen-related peptides (Dowell et al., 2006; Hatcher et al., 2008; Zhang et al., 
2008; Lee et al., 2010). Besides characterizing the peptides in a tissue, sampling peptide release 
from the brain is important for functional studies, and can involve sampling release from 
cultured cells and brain slices (Bora et al., 2008; Hatcher et al., 2008; Croushore and Sweedler, 
2013; Fan et al., 2013). Perhaps the best known approach for sampling brain neurochemistry is 
microdialysis (Ao and Stenken, 2006; Schultz and Kennedy, 2008; Bernay et al., 2009). Previous 
work has shown that there is a deficit in spontaneous alternation (a hippocampal-dependent task 
that measures working memory), as well as reduced release of at least one neurotransmitter, 
acetylcholine, due to opioid receptor activation (Costa et al., 1983; Bostock et al., 1988; 
Ragozzino et al., 1992; Gorman et al., 1994; Ragozzino and Gold, 1995; Ragozzino et al., 1995; 
Wan et al., 1995; McNay and Gold, 1998; McNay et al., 2006). Here, we used in vivo 
microdialysis paired with MS to examine the effects of morphine on peptide release in the 
hippocampus. We detected two peptides derived from the fibrinogen α-chain that were increased 
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in the microdialysate. One of the peptides was fibrinopeptide A (m/z 1738.80); the other was a 
fibrinopeptide A-derived peptide (m/z 1667.76) that results from the cleavage between amino 
acids A and D in the N-terminus. We used Fourier transform ion cyclotron resonance mass 
spectrometry (FT-ICR MS, or FTMS) to sequence these peptides. In particular, fibrinopeptide A 
was significantly upregulated in rats that had been given a morphine injection and placed on a 
four-arm radial maze to perform a spontaneous alternation task compared with rats given a saline 
injection and exposed to a spontaneous alternation task (p < 0.001), saline injection alone (p < 
0.01), or morphine injection alone (p < 0.01), respectively. These results suggest an interaction 
between fibrinogen and morphine in the brain.  
 
4.4 Materials and Methods 
4.4.1 Animals 
Adult male Sprague Dawley rats were housed in the animal facility at the Psychology 
Building (University of Illinois at Urbana-Champaign). Rats were singly housed in translucent 
cages maintained under controlled environmental conditions, with standard 12-h alternating 
periods of light and dark. Rodent chow and water were provided ad libitum.  Rats were handled 
daily for 5 min/day starting at least seven days before the behavioral experiments. Pain and 
discomfort were minimized throughout the study. Animal care, euthanasia, and other 
experimental procedures were in accordance with the Principles of Laboratory Animal Care 
(NIH Publication no. 85-23) and protocols approved by the University of Illinois at Urbana-
Champaign Institutional Animal Care and Use Committee; in addition, the ARRIVE guidelines 
were followed. Method optimization was performed on a total of n = 22 rats (n = 4, morphine; n 
= 5, saline; n = 8, morphine-testing; n = 5, saline-testing) to ensure the viability of the in vivo 
microdialysis sampling (data not shown). A total of n = 14 rats were used for the in vivo 
microdialysis experiments (n = 4, morphine; n = 3, saline; n = 3, morphine-testing; n = 4, saline-
testing), and an additional rat (n = 1) rat was used for an extended collection of in vivo 
microdialysate for peptide sequencing analysis. 
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4.4.2 In Vivo Microdialysis 
 Rats were anesthetized with isoflurane and placed in a stereotaxic apparatus. CMA/11 
guide cannulae (CMA Microdialysis AB, Kista, Sweden) were bilaterally implanted above the 
central portion of the ventral hippocampus (coordinates: –5.5 mm from the bregma; ± 4.8 mm 
lateral; –4.2 mm deep from the skull). Skull screws were inserted and the entire assembly was 
anchored in place with dental cement. Rats were monitored and allowed to recover for 
approximately one week. On the day of in vivo microdialysis collections, 3-mm CMA/11 
microdialysis probes (CMA Microdialysis AB) with 20 kDA cutoff membranes were inserted 
into the ventral hippocampi. Brains were perfused continuously with artificial cerebrospinal fluid 
(128 mM NaCl, 2.5 mM KCl, 1.3 mM CaCl2, 2.1 mM MgCl2, 0.9 mM NaH2PO4, 2.0 mM 
Na2HPO4, 1.0 mM dextrose, pH 7.4) at a rate of 2 µL/min. A constant perfusion rate throughout 
the in vivo microdialysis experiments was achieved by an automated CMA/100 microinjection 
pump (CMA Microdialysis AB). Rats received either an acute subcutaneous morphine injection 
(5 mg/kg) or saline injection (n = 4, morphine; n = 3, saline). Samples were collected every 10 
min before, during, and after injection for a total of 120 min. In a subsequent experiment, rats 
received either an acute subcutaneous morphine injection (5 mg/kg) or saline injection and were 
then placed in a four-arm radial maze for 20 min for spontaneous alternation testing (n = 3, 
morphine-testing; n = 4, saline-testing). Samples were collected every 10 min before, during, and 
after injection and testing, for a total of 120 min. Samples collected during the first hour of 
microdialysis were discarded to allow for baseline stabilization (Westerink and Timmerman, 
1999). Peptides were concentrated by solid phase extraction via pre-equilibrated C18 ZipTip 
pipette tips (Millipore, Billerica, MA, USA) in line with the perfusate output. Each ZipTip was 
eluted in 0.3 µL increments of 70% acetonitrile onto five spots on a Prespotted AnchorChip 
(PAC) target (Bruker Daltonics, Billerica, MA, USA). The in vivo microdialysis experiments 
were started between 8–9 AM to ensure consistency across experiments.   
Probe placements in the ventral hippocampi were previously verified with histology 
using another group of rats, with no errors found (Morris et al., 2010). Briefly, rats were deeply 
anesthetized with an overdose intraperitoneal injection of sodium pentobarbital (Sigma-Aldrich, 
St. Louis, MO, USA) and then perfused intracardially with 80 mL of 0.1 M phosphate-buffered 
saline (PBS) followed by 80 mL of 4% paraformaldehyde in 0.1 M phosphate buffer (PB). Rats 
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were then decapitated and the brains removed and placed into 4% paraformaldehyde in 0.1 M PB 
for ~72 hrs. The brains were transferred to a solution of 20% glycerol in 0.1 M PBS and stored 
for ~48 hrs. Frozen sections (40 µM) containing the microdialysis probe tracts were collected at 
–30 o C with a Leica 1800 cryostat (Leica Microsystems, Wetzlar, Germany). Sections were 
mounted onto gelatin-coated slides and stained with cresyl violet to visualize probe placements 
using a dissection microscope.  
 
4.4.3 Spontaneous Alternation Testing 
Spontaneous alternation performance was assessed in a four-arm plus-shaped black 
plexiglass maze with an open ceiling. The dimensions of each arm were 45 cm L × 13 cm W × 7 
cm H. The dimensions of the central square-shaped area were 13 cm L × 13 cm W × 7 cm H. 
The training room contained numerous extramaze visual cues in the form of objects and wall 
decorations. Rats were placed in a random start arm and were allowed to freely traverse the maze 
for 20 min. The numbers and sequences of entries were recorded and alternation scores were 
calculated. An alternation consisted of visiting all four arms within overlapping sets of five arm 
visits. Using this procedure, the total number of possible alternations was equal to the number of 
arm entries minus 4. The percent alternation score is equal to (actual alternations/possible 
alternations) × 100. Chance performance on this task is 44%. Spontaneous alternation 
performance was tested during the morning hours to ensure consistency across experiments.  
 
4.4.4 Analysis of Microdialysate by Mass Spectrometry 
Mass spectrometric analysis of the samples was performed using a matrix-assisted laser 
desorption/ionization time-of-flight / time-of-flight (MALDI-TOF/TOF) mass spectrometer 
(ultrafleXtreme, Bruker Daltonics). The instrument was externally calibrated using specified 
calibration spots on PAC targets. Samples were eluted onto the PAC targets as well.  For each of 
the microdialysis releasate fractions (five spots/ZipTip), data was collected using the 
AutoExecute
TM
 function with automated acquisition of spectra by panning across the spot with a 
total of 1000 laser shots (sum of 10 × 100 laser shots) and combing the spectra. Using the 
flexAnalysis 3.3 software package (Bruker Daltonics), mass spectra were smoothed and baseline 
corrected, and peaks were analyzed for intensity. 
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4.4.5 Peptide Extraction and Sequencing Analysis by FTMS  
Microdialysate collected over 3 h on two separate days from a morphine-injected rat (n = 
1) was subjected to sequencing analysis. Samples were collected at 1 h intervals using pre-
equilibrated C18 ZipTip pipette tips and eluted with 0.5 µL of 70% acetonitrile into low-bind 
tubes (Sigma-Aldrich). Tube contents from each 1 h collection were then combined, dried with a 
Savant SpeedVac Vacuum Concentrator (Thermo Scientific, Waltham, MA, USA), and 
reconstituted in 100 L of deionized water. The reconstituted samples were desalted using a C18 
spin column (Pierce, Rockford, IL, USA).  The eluted samples from the spin column were dried 
using the SpeedVac and then reconstituted in 20 µL of 95/5 H2O/acetonitrile and analyzed with 
an 11 Tesla linear trap quadrupole-FT mass spectrometer (LTQ-FT Ultra, ThermoFisher 
Scientific, San Jose, CA, USA) equipped with a 1D NanoLC pump (Eksigent Technologies, 
Dublin, CA, USA) (Lee et al., 2010; Lee et al., 2013). The flow rate was 300 nL/min and the 
gradient used was 0–35 min, 1–20% B; 35–55 min, 20–55% B; 55–60 min, 55–95% B; 60–63 
min, 95–95% B; 63–68 min, 95–5% B; 68–80 min, 5–5% B. The LTQ-FTMS analysis included 
a full scan event and data-dependent collision-induced dissociation tandem MS (MS/MS) scans 
of the three most abundant peaks from the full scan. The resulting LC-FTMS/MS spectra were 
searched against an intact rat database in a “neuropeptide” search mode using ProSight PC 2.0 
(ThermoFisher Scientific), with tolerances of  ±1.1 Da and ±10 ppm for intact mass and 
fragment, respectively. 
 
4.4.6. Statistics  
Statistical analyses were conducted using StatView statistical software (SAS Institute 
Inc., Cary, NC, USA). Student’s t-tests were performed to determine the statistical significance 
of the spontaneous alternation performance and arms visited. Repeated measures of analysis of 
variance (ANOVA) were conducted for group effects of peak intensity across collection time 
points. Post hoc analyses were conducted using the Fisher’s Protected Least Significant 
Difference test. For these measurements, p < 0.05 was considered statistically significant.  
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4.5 Results 
In vivo microdialysis with MS was used to characterize extracellular peptide level 
changes in the hippocampus of awake and freely moving rats in response to acute subcutaneous 
morphine injection (5 mg/ kg), saline injection, morphine injection (5 mg/ kg) paired with 
spontaneous alternation, and saline injection paired with spontaneous alternation, respectively. A 
morphine dose of 5 mg/ kg was found to impair working memory without affecting arm entries 
or motor activity during the spontaneous alternation task (Figure 4.1A, B; p < 0.05). Results 
from the behavioral tests indicated that morphine-injected rats (n = 3) visited the same number of 
arms as did saline-injected rats (n = 4), but spontaneous alternation scores were significantly 
lower (Figure 4.2A, B; p < 0.05). These results are consistent with previous work showing that 
morphine has a deleterious effect on spontaneous alternation scores (Bostock et al., 1988; 
Ragozzino et al., 1992; Ragozzino and Gold, 1995; Ragozzino et al., 1995; Wan et al., 1995; 
McNay and Gold, 1998; McNay et al., 2006). In addition, prior studies done on the medial 
septum, an area that has a high density of opioid receptors, have shown that intraseptal injections 
of an opioid agonist can impair learning and memory in rats (Bostock et al., 1988; Ragozzino et 
al., 1992; Ragozzino and Gold, 1995; Ragozzino et al., 1995; Wan et al., 1995; McNay and 
Gold, 1998; McNay et al., 2006). 
Two peaks (m/z 1667.76 and 1738.80) were consistently detected throughout the 
microdialysis collections in the four animal groups: (1) saline (n = 3), (2) morphine (n = 4), (3) 
saline-testing (n = 4), (4) morphine-testing (n = 3) (Figure 4.3A). The peaks were sequenced 
using a longer (3 h) microdialysate collection to collect a greater amount of peptide in order to 
have a enough peptide for sequencing. We confirmed that these masses correspond to two 
peptides derived from the fibrinogen α-chain; (1) fibrinopeptide A with m/z 1738.80 (Figure 
4.3B) and (2) a fibrinopeptide A-derived peptide with m/z 1667.76, missing the N-terminal 
residue as a result of cleavage between amino acids A and D at the N-terminus (Figure 4.3C). 
Others have also identified these masses as corresponding to fibrinogen α-chain peptides 
(Dowell et al., 2006). The peak intensity for each of the peaks was obtained for each collection 
time point. Repeated measures ANOVA showed significant differences between treatment 
groups (comparing saline, morphine, saline-testing, morphine-testing groups) in percent change 
from the baseline of fibrinopeptide A intensity, F(3,10) = 10.563, p < 0.01 (Figure 4.4). There 
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were significant differences across microdialysis collection time points (microdialysis; p < 
0.001) and significant interaction between treatment groups and microdialysis collection points 
(microdialysis*treatment group; p < 0.05). Fishers’s PLSD also revealed post-hoc effects 
showing increased intensity in the morphine-testing group (n = 3) compared with the saline 
group (n = 3; p < 0.01), saline-testing group (n = 4; p < 0.001), and morphine group (n = 4; p < 
0.01), respectively. Repeated measures ANOVA did not show any differences between treatment 
groups (comparing saline, morphine, saline-testing, morphine-testing groups) in percent change 
from the baseline of fibrinopeptide A-derived peptide intensity F(3,10) = 2.247, p = 0.146 
(Figure 4.5A, B (zoomed in)). There were no significant differences across microdialysis 
collection points (microdialysis; p = 0.0579) and no interaction between treatment groups and 
microdialysis collection points (microdialysis*treatment group; p = 0.1867). However, Fisher’s 
PLSD revealed post-hoc effect showing increased intensity in the morphine-testing group (n = 3) 
compared with the saline-testing group (n = 4; p < 0.05). A control peak at m/z 987.53, which 
was de novo sequenced (Figure 4.6A, B), was also analyzed in greater detail between all four 
groups. Data from one morphine-testing group rat was excluded from the control peak analysis 
because it did not contain the particular peak of interest. Repeated measures ANOVA did not 
reveal any differences between treatment groups (comparing saline, morphine, saline-testing, 
morphine-testing groups) in percent change from the baseline of peak m/z 987.53 intensity 
(Figure 4.7; p = 0.297). These results show that the changes observed for the fibrinogen-α-
derived peptides do not represent an overall increase in peptides and the changes are peptide 
specific. While other peptide peaks were detected, these peaks were not observed consistently 
across rats or conditions.  
 
4.6 Discussion 
Here, we have observed the effects of morphine on changes in extracellular peptide levels 
from the hippocampus utilizing in vivo microdialysis paired with MS. While many peaks were 
observed inconsistently, we found several that were observed consistently. A fibrinogen α-chain-
derived peptide, fibrinopeptide A, was upregulated in response to morphine and spontaneous 
alternation. Although this appears to be the first report of fibrinogen level changes in rat brain, 
human studies have shown that opium users have higher fibrinogen blood concentrations 
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(Galante et al., 1994; Asgary et al., 2008). In situ hybridization data form the Allen Mouse Brain 
Atlas show mRNA expression of fibrinogen chains in the mouse brain (©2012 Allen Institute for 
Brain Science. Allen Mouse Brain Atlas [Internet]. Available from: http://mouse.brain-map.org; 
Lein et al., 2007). Although these recent data suggest that fibrinogen is synthesized in the brain, 
further analysis is needed to confirm the expression, synthesis, and release of fibrinogen from 
neurons. Conversely, there are reports stating that fibrinogen is neither synthesized nor present in 
the brain as the brain-blood-barrier excludes it (Adams et al., 2004; Ahn et al., 2010). 
Furthermore, fibrinogen has been found in damaged vasculature/brain tissue and, in particular, 
accumulates in Alzheimer’s disease (Paul et al., 2007). Amyloid-beta interacts with fibrinogen 
and causes the formation of abnormally strong fibrin clots, a possible cause of the high number 
of blocked blood vessels that occurs in Alzheimer’s patients (Ahn et al., 2010; Cortes-Canteli et 
al., 2010). In addition, fibrinogen appears to be a mediator of inflammation at the blood-brain-
barrier; thus, the insertion of the microdialysis probes in our study might be one factor causing 
its levels to increase. Conversely, the observed increases in the levels of fibrinogen might 
indicate that it influences the effects of morphine. Buczko and Wiśniewski (1972) have shown 
that trypsin-digested fibrinogen degradation products can potentiate the actions of morphine. 
They also determined that degradation products smaller than approximately m/z 1500 actually 
abolished morphine’s analgesic activity (Buczko and Wiśniewski, 1972). 
It is also possible that morphine is directly involved in the increased levels of the 
fibrinogen α-chain-derived peptides we observed. Morphine has been reported to alter the release 
of neurotransmitters in the hippocampus, but there appear to be no reports of its effects on 
peptide release in the hippocampus. Previous studies have shown that intraseptal injections of 
opioid agonist can decrease the release of acetylcholine from the hippocampus (Costa et al., 
1983; Gorman et al., 1994; Ragozzino and Gold, 1995). In addition, in the medial septum, 
activation of opioid receptors seems to inhibit GABAergic interneurons that influence both 
cholinergic and GABAergic  neurons projecting to the hippocampus (Alreja et al., 2000).  
Furthermore, although we show that one fibrinogen α-chain peptide is upregulated with 
an acute morphine injection and spontaneous alternation, it is reasonable to speculate that other 
proteins in the blood clotting pathway are possibly affected. As one example, tPA, involved in 
fibrinolysis, is synthesized and released by neurons and has been shown to aid in sympathetic 
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neuronal function and transmitter release (Wu et al., 2000; Jacovina et al., 2001; Schaefer et al., 
2006). tPA is mostly synthesized by endothelial cells and is found in blood (Levin, 1983). By 
activating plasmin, tPA plays an indirect role in the cleavage of pro–brain-derived neurotrophic 
factor (proBDNF) into mature BDNF (mBDNF) (Pang et al., 2004). tPA itself is unable to cleave 
proBNDF; however, tPA together with plasminogen has been shown to be as effective as 
plasmin in generating mBDNF, suggesting that tPA affects proBDNF cleavage indirectly by 
activating plasmin (Pang et al., 2004). Perhaps tPA is upregulated in the hippocampus as well, 
which could in turn upregulate BDNF.  
The possible relationship to BDNF is of particular interest because of its role in many 
brain processes, including neuronal survival and differentiation (Alderson et al., 1990; 
Nonomura et al., 1995; Abiru et al., 1996; Nonner et al., 1996; Ha et al., 1999), synaptic 
plasticity (Poo, 2001), and long-term potentiation (Patterson et al., 1992; Kang et al., 1997). It is 
housed in large dense core vesicles (Fawcett et al., 1997; Michael et al., 1997; Haubensak et al., 
1998; Möller et al., 1998; Luo et al., 2001) and is released both via the constitutive and regulated 
secretory pathways (reviewed in Lessman et al. 2003). Interestingly, BDNF has also been shown 
to upregulate peptide mRNA synthesis and release in the cortex and hippocampus (Nawa et al., 
1994; Marty et al., 1997). Future work will determine whether morphine, in combination with a 
spontaneous alternation task, upregulates tPA activity and leads to more synaptic plasticity 
changes associated with BDNF.  
In conclusion, morphine combined with a spontaneous alternation task significantly 
increased the extracellular levels of fibrinopeptide A in the hippocampus. One possibility we 
considered is that local changes in fibrinopeptide A in the hippocampus are due to injury caused 
by the microdialysis probes combined with physical activity. However, after morphine injection 
the mobility of rats on the spontaneous alternation task remained unchanged compared to saline-
injected rats even though peptide release increased. This makes is unlikely that morphine’s 
analgesic effect allowed the rats to inadvertently cause greater trauma to the area that contains 
the microdialysis probes, and therefore upregulating fibrinogen peptides due to the injury. 
Although it is possible that fibrinogen degradation products potentiate morphine’s analgesic 
activity, the suggestion from Buczko and Wiśniewski (1972) linking morphine and fibrinogen 
actions cannot be explained due to an injury-induced effect. Regardless, the “local” increase in 
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specific fibrinogen-related peptides in the brain is intriguing, and the interplay between 
fibrinogen and morphine remains to be elucidated.   
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4.7 Figures 
 
Figure 4.1 Effects of morphine concentrations on spontaneous alternation and number of arms visited. Spontaneous alternation 
performance was assessed in a four-arm, plus-shaped black plexiglass maze with an open ceiling. Rats were placed in a random start 
arm and were allowed to traverse the maze freely for 20 min. The number and sequence of entries were recorded and alternation 
performance was calculated. An alternation consisted of visiting all four arms within overlapping sets of five arm visits. The total 
number of possible alternations was equal to the number of arm entries minus 4. (A) Spontaneous alternation scores from rats given an 
acute injection of saline (n = 5), 2 mg/kg morphine (n = 5), 5 mg/kg morphine (n = 5), and 10 mg/kg morphine (n = 5). The 5 mg/kg 
dose impaired the spontaneous alternation score (*, p < 0.05). (B) Number of arms visited from rats given an acute injection of saline 
(n = 5), 2 mg/kg morphine (n = 5), 5 mg/kg morphine (n = 5), and 10 mg/kg morphine (n = 5). The 5 mg/kg dose did not affect arm 
entries or motor activity during spontaneous alternation. The 10 mg/kg dose significantly reduced arm entries (*, p < 0.05). Error bars 
represent SEM.
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Figure 4.2 Effects of acute injection of 5 mg/kg morphine on spontaneous alternation and 
number of arms visited in rats undergoing in vivo microdialysis. Rats were subjected to the same 
spontaneous alternation parameters as in Fig. 1, in addition to having in vivo microdialysis 
probes inserted into the ventral hippocampus. (A) Spontaneous alternation scores from rats given 
an acute injection of saline (n = 4) or 5 mg/kg morphine (n = 3). Scores from rats treated with 
morphine are significantly reduced (*, p < 0.05). (B) Number of arms visited from rats given an 
acute injection of saline (n = 4) or 5 mg/kg morphine (n = 3). Morphine did not affect arm 
entries. Error bars represent SEM. 
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Figure 4.3 Sequencing of fibrinogen α-chain-derived peptides. Microdialysate was collected for 
3 h from a rat injected with morphine and tested on a spontaneous alternation task. The LTQ-FT 
Ultra mass spectrometer was used to sequence the particular peaks observed with high intensity 
in all animal groups and sample collections. (A) MALDI-MS spectrum showing peaks with m/z 
1738.80 and m/z 1667.76, consistently detected throughout the microdialysis collections. (B) 
FTMS and FTMS/MS spectra of fibrinopeptide A (ADTGTTSEFIEAGGDIR) with m/z 
1738.799, which was identified with 7 b-ions and 8 y-ions with high confidence (E value of 4.22 
× 10
-33
). Fibrinopeptide A was found to be derived from the fibrinogen α-chain. (C) FTMS and 
FTMS/MS spectra of a fibrinopeptide-A-derived peptide (DTGTTSEFIEAGGDIR) with m/z 
1667.762, identified with 14 b-ions and 12 y-ions with high confidence (E value of 1.98 x 10
-48
). 
The fibrinopeptide A-derived peptide was found to be derived from the fibrinogen α-chain.  
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Figure 4.4 Percent change from baseline of fibrinopeptide A (m/z 1738.80) intensity. Rats 
received either an acute subcutaneous morphine injection (5 mg/kg) or saline injection (n = 4, 
morphine; n = 3, saline). In a subsequent experiment, rats received either an acute subcutaneous 
morphine injection (5 mg/kg) or saline injection, and were additionally placed in a four-arm 
radial maze for 20 min for spontaneous alternation testing (n = 3, morphine-testing; n = 4, saline-
testing). In vivo microdialysate was collected every 10 min before, during, and after 
injection/testing, and analyzed by MS. Time collections are labeled as baseline (B), injection (I), 
and testing (T), and each label corresponds to a consecutive 10 min collection. The percent 
change from baseline was calculated by dividing the intensity of fibrinopeptide A at each 
particular time point by the average of the intensity of the first three baseline time points (B1, 
B2, B3). Repeated measures ANOVA showed significant differences between treatment groups 
(comparing saline, morphine, saline-testing, morphine-testing groups) in percent change from 
baseline of fibrinopeptide A intensity (p < 0.01). There were post-hoc effects showing increased 
intensity in the morphine-testing group (n = 3) compared to the saline group (n = 3; p < 0.01), 
saline-testing group (n = 4; p < 0.001), and morphine group (n = 4; p < 0.01). TreatmentGroup: 
p < 0.01; Microdialysis: p < 0.001; Microdialysis*TreatmentGroup: p < 0.05. Error bars 
represent SEM.
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Figure 4.5 Percent change from baseline of fibrinopeptide A-derived peptide (m/z 1667.76) intensity. Rats were subjected to the same 
experimental design as in Fig. 4. The percent change from baseline was calculated by dividing the intensity of fibrinopeptide A-
derived peptide at each particular time point by the average of the intensity of the first three baseline time points (B1, B2, B3). 
Repeated measures ANOVA did not show any significant differences between treatment groups (comparing saline, morphine, saline-
testing, morphine-testing groups) in percent change from baseline of fibrinopeptide A-derived peptide intensity (p = 0.146). There was 
a post-hoc effect showing increased intensity in the morphine-testing group (n = 3) as compared to the saline-testing group (n = 4; p < 
0.05). (A) A zoomed-out version of the graph and (B) a zoomed-in version of the graph. TreatmentGroup: p = 0.146; Microdialysis: 
p = 0.0579; Microdialysis*TreatmentGroup: p = 0.1867. Error bars represent SEM
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Figure 4.6 FTMS analysis of unknown m/z 987.53, a mass peak observed in 13 out of the total 
14 rats analyzed. Microdialysate was collected for 3 h from a rat injected with morphine and 
tested on a spontaneous alternation task. FTMS was used to sequence this particular peak 
observed with high intensity throughout animal groups and sample collections. (A) FTMS 
spectrum showing an unknown peptide. (B) FTMS/MS spectrum showing that this unknown 
peptide was unable to be identified as a peptide derived from any known prohormone precursors. 
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Figure 4.7 Percent change from baseline of m/z 987.53 intensity. Rats were subjected to the 
same experimental design as in Figs. 4 and 5. The percent change from baseline was calculated 
by dividing the intensity of the unknown at each particular time point by the average of the 
intensity of the first three baseline time points (B1, B2, B3). Repeated measures ANOVA 
showed no significant group differences (comparing saline, morphine, saline-testing, morphine-
testing groups) in percent change from baseline of unknown intensity (n = 3, saline; n = 3, 
morphine; n = 4, saline-testing; n = 3, morphine-testing; p = 0.297). Error bars represent SEM. 
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CHAPTER 5 
 
SUMMARY AND CONCLUSIONS 
 
This dissertation has focused on developing analytical protocols to characterize 
neuropeptide release. MS has a long history as a platform to identify and characterize peptides. 
Using various methods coupled to MS, the studies present here have shown the utility of 
analytical tools to analyze neuropeptide release from cells to animals using in vitro, ex vivo, and 
in vivo approaches.  
This work sheds light on the effect of a mutation in FMRP on peptide release and why a 
release deficit contributes to such a deleterious synaptic phenotype as seen in FXS. A more in 
depth list of peptides and their functions that are affected by this release deficit is needed. This 
information will provide additional insights into the role of peptides in synaptic remodeling. 
More work is needed to identify whether this peptide release deficit is specific to the brain or 
whether it has a more global effect in other organ systems. For example, blood serum could be 
investigated to see whether the same peptide release deficit is present in serum hormones. 
Additionally, it is worth speculating that other vesicle release machinery proteins could be 
affected by the lack of FMRP, as seen with a reduction in Rab3A expression. Future work could 
investigate the expression of proteins of the v-SNARE and t-SNARE complexes and their 
associated regulatory proteins. This work would greatly aid in uncovering the molecular 
mechanism that underlies the peptide release deficit seen in FXS. These data can also provide 
targets to increase peptide release as a pharmaceutical therapy for FXS.  
By measuring peptide release in a freely moving animal, this work also sheds light on the 
potential role of fibrinogen in working memory. Fibrinogen is a widely recognized blood clotting 
factor, but its role in the CNS is not as clearly understood. More work is needed to confirm its 
synthesis and expression in the brain, although this work provides data to support the in situ 
evidence for its presence in the hippocampus. Immunohistochemistry and Western blot 
expression confirmation of brain expression will help to support the data obtained via MS. While 
the data presented here provides some insight into the relationship between morphine and 
peptide release, further work is still needed to elucidate the interplay between morphine and 
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fibrinogen. Such future work should include other areas of the brain and their peptide prelease 
profiles in response to morphine. Additionally, exogenous addition/blocking of fibrinopeptide A 
should be investigated to determine whether it would case the same behavioral effects as seen in 
these studies.  
The research presented in this dissertation provides novel information about the 
physiological and behavioral effects of abnormally reduced peptide release (as seen in Fmr1 KO 
mice) and abnormally increased peptide release (as seen in rats treated with morphine). In 
addition, this work presents novel data supporting the role of fibrinogen in the brain, a surprising 
finding given the other roles associated with this protein.  
In conclusion, the research presented here used a variety of analytical methods to analyze 
disease states and demonstrates abnormal peptide release. Thus, this work provides insights into 
FXS and morphine abuse and can shed light into potential therapeutic targets.  
 
 
